Nicotinic treatment of Alzheimer's disease

Biological Psychiatry

Volumn 49, Issue 3, 2001, Pages 268-278

  Newhouse, Paul A ^a,d   Potter, Alexandra ^a   Kelton, Megan ^a,b   Corwin, June ^c  

^a UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

^b Lamont Doherty Earth Observatory   (United States)

^c NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d FLETCHER ALLEN HEALTH CARE   (United States)

Author keywords

ABT 418; Alzheimer's disease; Mecamylamine; Nicotine; Nicotinic agonists; Treatment

Indexed keywords

3 (2,4 DIMETHOXYBENZYLIDENE)ANABASEINE; 3 ETHYNYL 5 (1 METHYL 2 PYRROLIDINYL)PYRIDINE; 3 METHYL 5 (1 METHYL 2 PYRROLIDINYL)ISOXAZOLE; 4 [[2 (1 METHYL 2 PYRROLIDINYL)ETHYL]THIO]PHENOL; ATROPINE; CHOLINESTERASE; MECAMYLAMINE; MUSCARINIC RECEPTOR BLOCKING AGENT; N METHYL 4 (3 PYRIDINYL) 3 BUTENAMINE; NICOTINE; NICOTINIC AGENT; NICOTINIC RECEPTOR BLOCKING AGENT; SCOPOLAMINE;

ALLOSTERISM; ALZHEIMER DISEASE; ANXIETY; ARTICLE; CENTRAL NERVOUS SYSTEM; CHEMICAL STRUCTURE; CHOLINESTERASE INHIBITION; CLINICAL FEATURE; CLINICAL TRIAL; COGNITION; DOSE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; HUMAN; HYPOTHESIS; LONG TERM EXPOSURE; NAUSEA; NEUROPSYCHIATRY; NONHUMAN; PRIORITY JOURNAL; RESPONSE TIME; STIMULATION; TREATMENT OUTCOME; VERBAL BEHAVIOR; VISUAL INFORMATION; VOMITING;

EID: 0035251676     PISSN: 00063223     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-3223(00)01069-6     Document Type: Review

References (67)

1. Normalization of auditory physiology by cigarette smoking in schizophrenic patients
2. Normalization by nicotine of deficient auditory sensory gating in the relatives of schizophrenics
3. A randomized controlled trial of prednisone in Alzheimer's disease
4. Improved learning and memory in aged rats with chronic administration of the nicotinic receptor agonist GTS-21
5. Preclinical pharmacology of ABT-418: A prototypical cholinergic channel activator for the potential treatment of Alzheimer's disease
6. Comparative alterations of nicotinic and muscarinic binding sites in Alzheimer's and Parkinson's diseases
7. Cognitive psychology and human memory
8. The cholinergic hypothesis of geriatric memory dysfunction
9. Targacept compounds potentiate sub-maximal doses of tacrine and aricept
10. Anxiolytic-like effects of the novel cholinergic channel activator ABT 418
11. Improvement in performance of a delayed matching-to-sample task by monkeys following ABT-418: A novel cholinergic channel activator for memory enhancement
12. Human memory and the cholinergic system
13. Nicotine-like behavioral effect after small dose of mecamylamine in Roman high-avoidance rats
14. 3H]nicotine binding in human cerebral cortex: Comparison between Alzheimer's disease and the normal
15. Noncompetitive functional inhibition at diverse, human nicotinic acetylcholine receptor subtypes by bupropion, phencyclidine, and ibogaine
16. Nicotine reverses GABAergic inhibition of long-term potentiation induction in the hippocampal CA1 region
17. Nicotine and smoking: A review of effects on human performance
18. Effects of atropine on repeated acquisition and performance of response sequences in humans
19. Genetic and environmental aspects of the role of nicotinic receptors in neurodegenerative disorders: Emphasis on Alzheimer's disease and Parkinson's disease
20. Effects of acute subcutaneous nicotine on attention, information processing and short term memory in Alzheimer's disease
21. The effects of nicotine on Parkinson's disease
22. Nicotinic receptors stimulation protects neurons against beta-amyloid toxicity
23. RJR-2403: A nicotinic agonist with CNS selectivity II: In vivo characterization
24. Combined nicotinic and muscarinic blockade in elderly normal volunteers: Cognitive, behavioral, and physiological responses
25. The potential of subtype-selective neuronal nicotinic acetylcholine receptor agonists as therapeutic agents
26. Neuronal nicotinic receptors as novel drug targets
27. Allosteric modulation of nicotinic acetylcholine receptors as a treatment strategy for Alzheimer's disease
28. Effects of nicotine administered via a transdermal delivery system on vigilance: A repeated measure study
29. Selective effects of nicotine on attentional processes
30. The potential therapeutic usefulness of subtype selective neuronal nicotinic acetylcholine receptor agonists for the motor, cognitive, and disease progression components of Parkinson's disease
31. Estrogen replacement therapy for treatment of mild to moderate Alzheimer's disease: A randomized controlled trial
32. Clinical aspects of nicotinic agents: Therapeutic applications in central nervous system disorders
33. Acute nicotinic blockade produces cognitive impairment in normal humans
34. Age-related effects of the nicotinic antagonist mecamylamine on cognition and behavior
35. Effects of nicotinic cholinergic agents on cognitive functioning in Alzheimer's and Parkinson's disease
36. Effects of nicotinic agents on human cognition: Possible therapeutic applications in Alzheimer's and Parkinson's diseases
37. Neuroendocrine, physiologic, and behavioral responses following intravenous nicotine in nonsmoking healthy volunteers and in patients with Alzheimer's disease
38. Intravenous nicotine in Alzheimer's disease: A pilot study
39. Effect of long-term treatment with tacrine (THA) in Alzheimer's disease as visualized with PET
40. 11C-nicotine binding in normal and Alzheimer brains - In vivo assessment using positron emission tomography
41. Activation and inhibition of rat neuronal nicotinic receptors by ABT-418
42. Neuronal nicotinic receptors in the human brain
43. Baseline-dependency of nicotine effects: A review
44. Alteration in nicotinic binding sites in Parkinson's disease, Lewy body dementia, and Alzheimer's disease: Possible index of early neuropathology
45. Acute effects of the selective cholinergic channel activator (nicotinic agonist) ABT-418 in Alzheimer's disease
46. Central nicotinic receptor agonists ABT-418, ABT-089, and (-)nicotine reduce distractibility in adult monkeys
47. Effects of scopolamine on delayed-matching-to-sample and paired associates tests of visual memory and learning in human subjects: Comparison with diazepam and implications for dementia
48. Therapeutic approaches to Alzheimer's disease inflammation
49. Nicotine and THA: Evidence for improved attention in patients with dementia of the Alzheimer type
50. Treatment of Tourette's syndrome with mecamylamine
51. In vivo positron emission tomography studies on the novel nicotinic receptor agonist [11C] MP compared with [11C] ABT and (S) (-)[11C] nicotine in rhesus monkeys
52. The effects of nicotine in dermal plaster on cognitive functions in patients with Alzheimer's disease
53. Pragmatics of recognition memory: Application to dementia and amnesia
54. Differential responsivity of mood, behavior, and cognition to cholinergic agents in elderly neuropsychiatric populations
55. Dose-specific improvements in memory-related performance by rats and aged monkeys administered the nicotinic-cholinergic antagonist mecamylamine
56. Lu 25-109, a muscarinic agonist, fails to improve cognition in Alzheimer's disease Lu25-109 Study Group
57. Cholinergic control of cognitive resources
58. Epibatidine and ABT 418 reveal selective losses of alpha 4 beta 2 nicotinic receptors in Alzheimer brains
59. Selectivity of cholinesterase inhibition clinical implications for the treatment of Alzheimer's disease
60. Four-week nicotine skin patch treatment effects on cognitive performance in Alzheimer's disease
61. Nicotinic acetylcholine binding sites in Alzheimer's disease
62. Basal forebrain neurons in dementia of Parkinson's disease
63. 3H] nicotinic acetylcholine binding in Alzheimer's disease and Parkinson's disease: An autoradiographic study
64. A controlled trial of ABT-418 in attention deficit hyperactivity disorder in adults
65. Nicotine patches in Alzheimer's disease: Pilot study on learning, memory, and safety
66. Cholinergic switching within neocortical inhibitory networks
67. Nicotine modulates the neurotoxic effect of beta-amyloid protein (25-35) in hippocampal cultures